2017

Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

  • Hong D, Tolcher A, Sullivan R, Shapiro G, Chmielowski B, Ribas A, Brail L, Pearlberg J, Mahabhashyam S, Lee L, Dansky Ullman C, O’Connell B, Kutok J, Postow M, Wolchok J. Monotherapy dose escalation clinical and translational data from first-in-human study in advanced solid tumors of IPI-549, an oral, selective, PI3K-gamma inhibitor targeting tumor macrophages.
  • Ribas A, Hong D, Tolcher A, Sullivan R, Shapiro G, Chmielowski B, Brail L, Lee L, Mahabhashyam S, Dansky Ullman C, Postow P, Wolchok J. A phase 1/1b first-in-human study of IPI-549, a PI3K-gamma, as a monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.

AACR Annual Meeting 2017

  • Tolcher A, Hong D, Sullivan R, Mier J, Shapiro G, Chmielowski B, Ribas A, Postow M, Pearlberg J, Brail L, Lee L, Dansky Ullmann C, Wolchok J. IPI-549-01 – A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors.
  • Kutok, J. Overcoming resistance to checkpoint blockade by selectively targeting PI3K-gamma.

Keystone Symposia on Molecular and Cellular Biology: PI3K Pathways in Immunology, Growth Disorders and Cancer 

  • Kutok, J. The PI3K-gamma inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and overcomes immune checkpoint blockade resistance in preclinical models.

2016

Nature

  • Kaneda M, Messer K, Ralainirina N, Li H, Leem C, Gorjestani S, Woo G, Nguyen A, Figueiredo C, Foubert P, Schmid M, Pink M, Winkler D, Rausch M, Palombella V, Kutok J, McGovern K, Frazer K, Wu X, Karin M, Sasik R, Cohen E, Varner J.
  • De Henau O, Rausch M, Winkler D, Campesato L, Liu C, Hirschhorn-Cymerman D, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella V, McGovern K, Kutok J, Wolchok J, Merghoub T. Overcoming resistance to checkpoint blockade therapy by targeting

CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

  • Tolcher A, Hong D, Sullivan R, Mier J, Shapiro G, Pearlberg J, Brail L, Lee L, Han L, Dansky Ullman C, Stern H, Wolchok J. A phase 1/1b first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.
  • Rausch M, Tchaicha J, Tibbitts T, De Henau O, Sharma S, Pink M, Gladstone J, Proctor J, Douglas M, Stern H, Merghoub T, Wolchok J, McGovern K, Kutok J, Winkler D. The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment.

ACS Medicinal Chemistry Letters

  • , , , , D, , , ,  

American Association for Cancer Research Annual Meeting 2016

  • Henau O, Merghoub T, Winkler D, Sharma S, Pink M, Tchaicha J, Rausch M,  Proctor J, Kosmider N, Soglia J, Palombella V,  Kutok J, Wolchok J, McGovern K. Checkpoint Blockade Therapy is Improved by Altering the Immune Suppressive Microenvironment with IPI-549, a Potent and Selective Inhibitor of PI3K-gamma, in Preclinical Models

2015

American Association for Cancer Research Inaugural International Cancer Immunotherapy Conference 2015

  • Kutok J, Ali J, Brophy E, Castro A, DiNitto J, Evans C, Faia K, Goldstein S, Kosmider N, Lescarbeau A, Liu T, Martin C, McGovern K, Nair S, Pink M, Proctor J, Rausch M, Sharma S, Soglia J, Tchaicha J, Tremblay M, Walsh K, White K, Winkler D, Palombella V. The Potent and Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor, IPI-549, Inhibits Tumor Growth in Murine Syngeneic Solid Tumor Models through Alterations in the Immune Suppressive Microenvironment